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Abstract
This study aimed to develop a modular, diagnostic algorithm for extended spectrum b-lactamase (ESBL) detection in Enterobacteriaceae.
Clinical Enterobacteriaceae strains (n = 2518) were screened for ESBL production using Clinical and Laboratory Standards Institute (CLSI)
breakpoints for third-generation cephalosporins and by synergy image detection (clavulanic acid/extended-spectrum cephalosporins).
Isolates screening positive for ESBL (n = 242, 108 by critical CLSI diameters alone, five by double disk synergy test (DDST) alone, and
129 by both critical diameters and DDST) and 138 ESBL screening negative isolates (control group) were investigated by molecular
methods considered to be the reference standard (multiplex CTX-M type PCR, TEM and SHV type sequence characterization). One
hundred and twenty-four out of 242 Enterobacteriaceae isolates screening positive for ESBL were confirmed to be ESBL positive by the
reference standard, the majority of them in E. coli, K. pneumoniae and E. cloacae (94, 17 and nine isolates, respectively). Prevalence of
ESBL production ranged from <1% for P. mirabilis to 4.7%, 5.1% and 6.6%, for K. pneumoniae, E. cloacae and E. coli, respectively. Combin-
ing CLSI ceftriaxone and cefpodoxime critical ESBL diameters was found to be the most sensitive phenotypic screening method (sensi-
tivity 99.2%). Combining critical diameters of cefpodoxime and ceftriaxone with DDST for cefpodoxime resulted in a sensitivity of
100%. For phenotypic confirmation, combining the CLSI recommended combined disk test (CDT) for ceftazidime and cefotaxime
amended with a cefepime CDT was highly sensitive (100%) and specific (97.5%). With respect to the studied population, the diagnostic
ESBL algorithm developed would have resulted in sensitivity and specificity of 100%. The corresponding flow chart is simple, easy to
use, inexpensive and applicable in the routine diagnostic laboratory.
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Introduction
Increasing prevalence of multidrug-resistant Gram-negative
bacteria has continuously been reported over the past years,
in particular Enterobacteriaceae producing extended spectrum
b-lactamases (ESBLs). ESBLs have the ability to hydrolyse
penicillins, first- second- and third-generation cephalosporins
and aztreonam (but not cephamycins or carbapenems), and
their activity is decreased by inhibitors such as clavulanic acid
[1]. ESBL-producing organisms may be responsible for life-
threatening infections, leading to increased morbidity, mor-
tality and healthcare-associated costs [2–5].
Klebsiella pneumoniae and Escherichia coli are the most fre-
quently isolated ESBL-producing strains worldwide; however,
ESBLs have been identified in other members of the Entero-
bacteriaceae family [6]. Most ESBLs can be classified in TEM,
SHV and CTX-M types [7]. To date, over 100 SHV- and 150
TEM-ESBL types and approximately 90 CTX-M variants (clus-
tered in five groups, CTX-M-1, CTX-M-2, CTX-M-8, CTX-
M-9 and CTX-M-25) have been identified (for actual update
see http://www.lahey.org/studies). In recent years CTX-M
type b-lactamase-producing E. coli have emerged and now
represent the most prevalent ESBL type in Europe and
North America [8,9].
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Until 2009 the Clinical and Laboratory Standards Institute
(CLSI) recommended adjusting the results of in vitro drug
susceptibility testing for penicillins, cephalosporins, cefepime
and monobactams and reporting these compounds as resis-
tant to ESBL-producing isolates of E. coli, K. pneumoniae,
Klebsiella oxytoca and Proteus mirabilis [10]. In 2010, the CLSI
released new cephalosporin susceptibility breakpoints for
Enterobacteriaceae. Subsequent adjustment of in vitro suscepti-
bility test results for b-lactams due to ESBL production is no
longer recommended, but screening for ESBL-producing iso-
lates is still considered useful and should be continued for
epidemiological reasons [11]. The new CLSI strategy is
widely in agreement with the guidelines of the European
Committee for Antimicrobial Susceptibility Testing
(EUCAST), which considers screening for ESBL-producing
isolates mandatory for epidemiological purposes [12].
Different phenotypic tests for ESBL detection have been
evaluated and described in the literature. However, little
information is available on the performance parameters of
standardized approaches combining single methods to iden-
tify ESBL-producing Enterobacteriaceae spp. [13–15]. The aim
of this study was to develop and prospectively evaluate a
standardized, inexpensive and simple approach that is able to
detect ESBL-producing Enterobacteriaceae isolates in a routine
clinical laboratory.
Methods
Clinical isolates
In this prospective study all non-duplicate clinical Enterobacte-
riaceae isolates (n = 2518) isolated over a period of
7 months from October 2009 until April 2010 were system-
atically screened for ESBL production. Only isolates that
were considered clinically relevant were included. Table 1
shows the study design, the numbers of studied clinical iso-
lates and the overview of ESBL detection results. Two hun-
dred and forty-two of the 2518 clinical isolates were
selected for further characterization on the basis of (i) posi-
tive CLSI screening cut-off values for ESBL for at least one
third-generation cephalosporin tested, and/or (ii) observation
of a synergy zone between amoxicillin-clavulanic acid and cef-
podoxime and/or ceftazidime, and/or ceftriaxone and/or cef-
otaxime. Of the 242 ESBL suspicious isolates, 108 were
selected by critical CLSI diameters alone, five by double disk
synergy test (DDST) alone, and 129 by both critical diame-
ters and DDST. Ninety-one of the 242 ESBL suspicious iso-
lates additionally produced an AmpC enzyme.
To assess sensitivity of the initial screening procedure a neg-
ative control group (138 negative in the ESBL screening) was
selected, in which species distribution resembled that of the
2518 study isolates (representative sample). The 138 control
isolates showed: (i) negative ESBL CLSI screening cut-off values
for all third-generation cephalosporins tested; and (ii) no visi-
ble synergy zone between a b-lactamase inhibitor disk and a
third-generation cephalosporin disk. To develop and evaluate
the ESBL detection algorithm the 380 isolates (242 positive
isolates screening positive for ESBL and 138 negative control
isolates) were characterized for ESBL production by a combi-
nation of phenotypic screening and confirmation methods,
with genetic methods (CTX-M-Multiplex PCR, TEM and SHV
sequencing) serving as the reference standard (Table 1).
Susceptibility testing
For susceptibility testing the disk diffusion method according
to Kirby-Bauer was used. Antibiotic disks (Becton Dickinson,
Franklin Lakes, NJ, USA) were selected and results were inter-
preted according to the guidelines of the CLSI [11]. The
following ESBL CLSI screening cut-off values were used for
third-generation cephalosporins: cefpodoxime (10 lg/disk)
£ 17 mm, ceftazidime (30 lg/disk) £ 22 mm, cefotaxime
(30 lg/disk) £ 27 mm, and ceftriaxone (30 lg/disk) £ 25 mm.
Susceptibility testing was carried out on Mueller-Hinton agar
(bioMe´rieux, Marcy L’Etoile, France) using McFarland 0.5 from
overnight cultures followed by incubation at 35C for 16–18 h.
AmpC-b-lactamase (AmpC) detection
All isolates included in this study were systematically charac-
terized for the production of an AmpC type b-lactamase as
described [16]. In brief, a multiplex PCR was used for detec-
tion of plasmid-mediated ampC b-lactamase genes, which
detects the six plasmid-mediated ampC families. The ampC
promoter mutation analysis of E. coli isolates was carried out
as described previously [17].
Double disk synergy test (DDST)
The double disk synergy test was conducted as described
[14]. Synergy images were recorded between amoxicillin-cla-
vulanic acid disks (20/10 lg/disk) and cefpodoxime, ceftazi-
dime, ceftriaxone or cefotaxime disks. Antibiotic disks were
placed 27 mm apart, centre-to-centre. b-lactam inhibitor-
mediated enhancement of the third-generation cephalosporin
inhibition zone was interpreted as synergy positive.
Combined disk test (CDT)
The CLSI recommended combined disk test (CDT) was per-
formed with ceftazidime and cefotaxime disks with and with-
out clavulanic acid [10]. Additionally, disks containing 30 lg
cefepime and 30 lg cefepime/10 lg clavulanic acid were pro-
duced for this study (Liofilchem, Roseto degli Abruzzi, Italy)
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because this combination was not available from Becton Dick-
inson. AmpC non-producing strains were inoculated on Muel-
ler-Hinton agar using McFarland 0.5 followed by incubation at
35C for 16–18 h. For AmpC-producing isolates CDT was
compared on Mueller-Hinton agar and Mueller-Hinton agar
containing 250 mg/L of cloxacillin (AES CHEMUNEX, Bruz
Cedex, France). A difference in the inhibition zone diameters
of ‡5 mm for any third-generation cephalosporin/clavulanic
acid combination vs. the corresponding third-generation ceph-
alosporin alone was considered indicative of ESBL production.
TEM and SHV ESBL identification
DNA was extracted from colonies grown on sheep blood agar
medium using the InstaGene Matrix (Bio-Rad, Reinach, Swit-
zerland) following the manufacturer’s instructions. Molecular
TEM and SHV ESBL detection was carried out as described
elsewhere [18]. TEM and SHV b-lactamase sequences were
compared with E. coli AF427133.1 TEM-1 and E. coli AF148850
SHV-1 using the publicly available database at http://www.
lahey.org/studies. Each sequence electropherogram was
screened for the presence of double peak signals, which would
indicate the presence of multiple SHV or TEM variants.
CTX-M b-lactamase gene identification
For the detection of CTX-M b-lactamase genes a multiplex
PCR was performed as described by Pitout et al. [8]. This
multiplex PCR detects the CTX-M group 1, CTX-M group 2,
CTX-M group 8 (former group III) and CTX-M group 9 (for-
mer group IV) genes. In the case of K. oxytoca, the CTX-M
primers for group 8 (former group III) also target similar
DNA sequences in the chromosomal K1 gene. To discrimi-
nate K1 from CTX-M group 8 amplification, CTX-M group 8
(former group III) genes in K. oxytoca were confirmed in a
second step by amplification of a 666 bp fragment using
primers ‘group 8 forward’ (5¢-TCGCGTTAAGCGGATGA
TGC-3¢) and ‘group 8/25 reverse’ (5¢-AACCCACGATGTGG
GTAGC-3¢) as published by Woodford et al. [19].
Interpretation
Molecular methods were considered to be the reference
standard for calculation of performance parameters.
Results
Screening and confirmation of Enterobacteriaceae isolates
for ESBL production
One hundred and twenty-four initial isolates screening posi-
tive for ESBL were confirmed as ESBL producers by pheno-
typic and molecular methods (Table 2). The majority of ESBL
producers were found in E. coli, K. pneumoniae and E. cloacae
(94, 17 and 9 isolates, respectively). Prevalence of ESBL pro-
duction ranged from <1% for P. mirabilis to 4.7%, 5.1% and
6.6% for K. pneumonia, E. cloacae and E. coli, respectively. The
mean prevalence of ESBL production in the 2518 Enterobacte-
TABLE 2. ESBLs detected in Enterobacteriaceae clinical isolates
Isolates
(n, %)
ESBL screening
positives (n, % of
isolates)
Confirmed
ESBLs
(n, % of
isolates)
CTX-M types (N, % of all ESBL)
SHV ESBL type
(n, % of all ESBL)
TEM ESBL type
(n, % of all ESBL)Group 1 Group 8 Group 9
All species 2518 (100.0) 242 (9.5) 124 (4.9) 86 (69.4) 1 (0.8) 23 (18.5) 11 (8.9) 3 (2.4)
Escherichia coli 1435 (57.0) 136 (9.5) 94 (6.6) 66 1 17 8 2
Klebsiella pneumoniae 360 (14.2) 31 (8.6) 17 (4.7) 14 0 2 1 0
Enterobacter cloacae 178 (7.1) 34 (19.1) 9 (5.1) 6 0 3 0 0
Proteus mirabilis 131 (5.2) 2 (1.5) 1 (0.8) 0 0 0 0 1
Klebsiella oxytoca 99 (3.9) 17 (17.2) 2 (2.0) 0 0 1 1 0
Citrobacter. spp. 1 (0.1) 1 (100.0) 1 (100.0) 0 0 0 1 0
Othersa 314 (12.5) 14 (4.5) 0
Numbers are given for all Enterobacteriaceae species that were isolated and tested for antibiotic susceptibility during the study period. Isolates that were considered part of
normal or colonization flora or rarely isolated species (<0.1% of all isolates in the study period) were not included.
aOthers comprised Citrobacter koseri (74 isolates), Proteus vulgaris (26 isolates), Enterobacter aerogenes (52 isolates), Citrobacter freundii (54 isolates), Morganella morganii (33 iso-
lates), Serratia marcescens (51 isolates), Hafnia alvei (20 isolates) and Salmonella enterica (4 isolates).
TABLE 3. Distribution of ESBL-producing Enterobacteria-
ceae isolates by sample origin
Sample origin
Enterobacteriaceae
isolates (n, %)
ESBL isolates
(n, %)
Urine 1002 (39.8) 64 (51.6)
Wound 332 (13.2) 12 (9.7)
Respiratory tracta 264 (10.5) 15 (12.1)
Groin 81 (3.2) 16 (12.9)
Blood culture 209 (8.3) 2 (1.6)
Vagina 40 (1.6) 2 (1.6)
Miscellaneous 546 (21.7) 4 (3.2)
Unknownb 43 (1.7) 9 (7.3)
Total 2518 (100) 124 (100)
aRespiratory material includes sputum, tracheal secretion and bronchoalveolar
lavage fluid.
bUnknown origin represents swabs without localization sent to the laboratory
for ESBL screening.
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riaceae isolates was 4.9% (Table 2). The highest proportion
of false-positive ESBL screening tests was observed with
E. cloacae and K. oxytoca isolates (Table 2).
CTX-M type genes were predominantly detected among
ESBL strains (88.7% of all ESBL), with CTX-M group 1 as the
most frequently identified subtype (69.4%). The second most
TABLE 4. Performance parameters of methods for detection of ESBL production in Enterobacteriaceae calculated for the
complete study population
Method/Method combination Isolates (n) TP (n) FP (n) TN (n) FN (n) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Critical diameters
CPD 2518 119 86 2308 5 96.0 96.4 58.0 99.8
CAZ 2518 90 67 2327 34 72.6 97.2 57.3 98.6
CTX 2518 121 93 2301 3 97.6 96.1 56.5 99.9
CRO 2518 122 83 2311 2 98.4 96.5 59.5 99.9
CRO and CPD 2518 123 99 2295 1 99.2 95.9 55.4 99.9
CRO and CAZ 2518 122 89 2305 2 98.4 96.3 57.8 99.9
CRO and CTX 2518 122 99 2295 2 98.4 95.9 55.2 99.9
CPD and CTX 2518 122 104 2290 2 98.4 95.7 54.0 99.9
CPD and CAZ 2518 121 91 2297 3 97.6 96.2 57.1 99.9
CTX and CAZ 2518 122 97 2303 2 98.4 96.0 55.7 99.9
CRO and CPD and CTX 2518 123 110 2284 1 99.2 95.4 52.8 99.9
DDST
Synergy AMC CPD 2518 109 16 2378 15 87.9 99.3 87.2 99.4
Synergy AMC CAZ 2518 105 10 2384 19 84.7 99.6 91.3 99.2
Synergy AMC CTX 2518 109 12 2385 12 90.1 99.5 90.1 99.5
Synergy AMC CRO 2518 115 6 2389 8 93.5 99.7 95.0 99.7
Synergy AMC CPD and/or CAZ 2518 113 18 2376 11 91.1 99.2 86.3 99.5
Critical diameters plus DDST
CRO and CPD plus synergy AMC CPD 2518 123 108 2287 0 100.0 95.5 53.2 100.0
CDT
CAZ CLA/CAZ 2518 102 2 2392 21 82.9 99.9 98.1 99.1
CTX CLA/CTX 2518 122 1 2393 1 99.2 100.0 99.2 99.9
FEP CLA/FEP 2518 112 1 2393 11 91.1 100.0 99.1 99.5
CAZ CTX FEP plus/minus CLA combined 2518 123 3 2391 0 100.0 99.9 97.6 100.0
ESBL algorithm 2518 123 0 2394 0 100.0 100.0 100.0 100.0
CPD, cefpodoxime; CAZ, ceftazidime; CTX, cefotaxime; CRO, ceftriaxone; FEP, cefepime; AMC, amoxicillin-clavulanic acid; CAZ CLA vs. CAZ, ceftazidime-clavulanic acid;
CTX CLA vs. CTX, cefotaxime-clavulanic acid; FEP CLA vs. FEP, cefepime-clavulanic acid; TP, true positive; TN, true negative; FP, false positive; FN, false negative; PPV, posi-
tive predictive value; NPV, negative predictive value; DDST, double disk synergy test; CDT, double disk synergy test. A combination of methods was rated positive if at least
one parameter was positive.
TABLE 5. Performance parameters of methods for detection of ESBL production in Enterobacteriaceae for ESBL screening
positive isolates
Method/Method combination Isolates (n) TP (n) FP (n) TN (n) FN (n) Sensitivity (%) Specificity (%)
Critical diameters
CPD 242 119 86 32 5 96.0 27.1
CAZ 242 90 67 51 34 72.6 43.2
CTX 242 121 93 25 3 97.6 21.2
CRO 242 122 83 35 2 98.4 29.7
CRO and CPD 242 123 99 19 1 99.2 16.1
CRO and CAZ 242 122 89 29 2 98.4 24.6
CRO and CTX 242 122 99 19 2 98.4 16.1
CPD and CTX 242 122 104 14 2 98.4 11.9
CPD and CAZ 242 121 91 27 3 97.6 22.9
CTX and CAZ 242 122 97 21 2 98.4 17.8
CRO and CPD and CTX 242 123 110 8 1 99.2 6.8
DDST
Synergy AMC CPD 242 109 16 102 15 87.9 86.4
Synergy AMC CAZ 242 105 10 108 19 84.7 91.5
Synergy AMC CTX 242 109 12 109 12 90.1 90.1
Synergy AMC CRO 242 115 6 113 8 93.5 95.0
Synergy AMC CPD and/or CAZ 242 113 18 100 11 91.1 84.7
Critical diameters plus DDST
CRO and CPD plus synergy AMC CPD 242 123 108 11 0 100.0 9.2
CDT
CAZ CLA/CAZ 242 102 2 116 21 82.9 98.3
CTX CLA/CTX 242 122 1 117 1 99.2 99.2
FEP CLA/FEP 242 112 1 117 11 91.1 99.2
CAZ CTX FEP plus/minus CLA combined 242 123 3 115 0 100.0 97.5
ESBL algorithm 242 123 0 118 0 100.0 100.0
CPD, cefpodoxime; CAZ, ceftazidime; CTX, cefotaxime; CRO, ceftriaxone; FEP, cefepime; AMC, amoxicillin-clavulanic acid; CAZ CLA vs. CAZ, ceftazidime-clavulanic acid;
CTX CLA vs. CTX, cefotaxime-clavulanic acid; FEP CLA vs. FEP, cefepime-clavulanic acid; TP, true positive; TN, true negative; FP, false positive; FN, false negative; DDST,
double disk synergy test; CDT, double disk synergy test. A combination of methods was rated positive if at least one parameter was positive.
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frequently isolated subtype was CTX-M group 9 (18.5%);
SHV and TEM ESBL types were observed in 8.9% and 2.4%
of all ESBL-producing isolates, respectively (Table 2).
Enterobacteriaceae species were isolated from different
clinical materials (Table 3). The majority of ESBL isolates was
isolated from urine (51.6%), groin (12.9%), respiratory tract
(12.1%) and wound (9.7%) specimens.
All 138 isolates of the negative control group (initial ESBL
screening negative) were confirmed ESBL negative by molec-
ular methods. This result was extrapolated to all 2276
isolates negative in initial screening for ESBL and perfor-
mance parameters of all tests and the algorithm including
positive predictive value (PPV) and negative predictive value
(NPV) were recalculated (Table 4).
Comparison of primary screening markers for ESBL
production
Considering critical diameters as the primary screening mar-
ker for ESBL detection, ceftriaxone showed the highest sen-
sitivity (98.4%). One ESBL-producing isolate was detected
exclusively by the critical diameter of cefpodoxime; this iso-
late was also positive with the cefpodoxime and ceftazidime
DDST. Ceftazidime diameters alone showed the lowest sen-
sitivity for ESBL detection (72.6%). The most sensitive com-
bination was ceftriaxone with cefpodoxime (sensitivity
99.2%); adding cefotaxime to these two substances did not
result in a further increase of sensitivity (Table 5). One
ESBL-positive isolate was exclusively detected by the DDST
with cefpodoxime and/or ceftazidime compared with both
critical diameters and the other DDSTs.
Combining critical diameters for ceftriaxone and cefpo-
doxime with the cefpodoxime DDST resulted in a sensitivity
of 100% for the potentially ESBL-producing clinical strains
used in this study (Table 5). Of 16 false-positive cefpodoxime
DDST, one was observed in E. cloacae, one in K. pneumoniae,
six in E. coli and eight were seen with K. oxytoca. Of 10 false-
positive ceftazidime DDST, four occurred with E. coli, four
with K. oxytoca, and two with K. pneumoniae. Of 12 false-
positive cefotaxime DDST, five were observed with E. coli
and seven were seen in K. oxytoca. Of six false-positive ceftri-
axone DDST, two were seen in E. coli and four in K. oxytoca.
Two of the E. coli isolates listed above showed false-positive
DDSTs for all screening agents (cefpodoxime, ceftazidime,
cefotaxime and cefepime). One of these isolates produced a
CIT type AmpC. Of the 124 confirmed ESBL producers, 10
were detected by critical CLSI diameters alone, one by the
DDST alone, and 113 by both methods.
Evaluation of confirmation assays for ESBL production
The CLSI recommended CDTs with ceftazidime and/or cefo-
taxime and clavulanic acid as inhibitors were compared as
phenotypic confirmation tests using molecular methods as
the reference standard. Additionally, a cefepime CDT with
clavulanic acid as inhibitor was evaluated. All third-generation
cephalosporin-clavulanic acid combinations showed a specific-
ity of >98.3%. For the ceftazidime CDT a sensitivity of 82.9%
was observed; cefotaxime and cefepime CDTs showed a sen-
sitivity of 99.2% and 91.1%, respectively (Table 5). Four
ESBL-positive isolates were detected by the cefotaxime CDT
alone; one ESBL was detected by the cefepime CDT alone.
In contrast, the ceftazidime CDT alone did not identify any
ESBL-producing isolates. If all CDTs were combined, sensitiv-
ity and specificity were 100% and 97.5%, respectively. Extrap-
olated to the 2518 study isolates, the sensitivity, specificity,
PPV and NPV of all CDTs combined were 100%, 99.9%,
97.6% and 100%, respectively (Table 4).
Using 91 AmpC-positive ESBL screening positive isolates
(Table 1), the three CDTs were compared on Mueller-
Hinton agar and Mueller-Hinton agar supplemented with
cloxacillin. A significantly increased overall sensitivity of the
TABLE 6. Comparison of performance parameters of combined disk tests in AmpC b-lactamase-positive putative ESBL-pro-
ducing isolatesa on Mueller-Hinton agar plates with and without supplementation of cloxacillin
Method Isolates (n) TP (n) FP (n) TN (n) FN (n) Sensitivity (%) Specificity (%)
MH with cloxacillin
CAZ CLA/CAZ 91 10 2 76 3 76.9 97.4
CTX CLA/CTX 91 13 0 78 0 100 100
FEP CLA/FEP 91 13 0 78 0 100 100
CAZ CTX FEP plus/minus CLA combined 91 13 2 76 0 100 97.4
MH without cloxacillin
CAZ CLA/CAZ 91 8 2 76 5 61.5 97.4
CTX CLA/CTX 91 10 0 78 3 76.9 100
FEP CLA/FEP 91 11 0 78 2 84.6 100
CAZ CTX FEP plus/minus CLA combined 91 11 2 76 2 84.6 97.4
CAZ CLA vs. CAZ, ceftazidime-clavulanic acid; CTX CLA vs. CTX, cefotaxime-clavulanic acid; FEP CLA vs. FEP, cefepime-clavulanic acid; TP, true positive; TN, true negative;
FP, false positive; FN, false negative; DDST, double disk synergy test; CDT, double disk synergy test. A combination of methods was rated positive if at least one parameter
was positive.
aIsolates consist of 54 isolates with known chromosomal ampC, 24 isolates harbouring a plasmidic ampC (22 CIT-type and 2 DHA-type AmpC) and 13 E. coli isolates with
promoter/attenuator mutations resulting in ampC overexpression; see also Table 2.
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FIG. 1. Diagnostic approach combining screening and confirmation of ESBL production in Enterobacteriaceae. Proposed diagnostic algorithm for
detection and confirmation of ESBL. CPD, cefpodoxime; CRO, ceftriaxone; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; AMC, amoxicil-
lin-clavulanic acid; CDT, combined disk test. (a) For isolates with positive AmpC screening or species with known chromosomal AmpC, the use
of Mueller-Hinton agar with cloxacillin is recommended. (b) For Klebsiella oxytoca, Citrobacter koseri and Citrobacter amalonaticus use CAZ for
CDT confirmation testing only. (c) Results for two isolates in this study were considered borderline or inconclusive, because only one of the
three CDT tests was marginally positive. For both isolates ESBL genes were not detected by PCR methods. No general recommendations can
be deduced because only two isolates were considered borderline. The borderline category was created to allow clinical microbiologists to sub-
ject indifferent or questionable results to further analyses. (d) Isolates that are ESBL screening positive regarding critical diameters of third-gener-
ation cephalosporins, but negative with the CDT, should be checked for the presence of AmpC enzymes and/or carbapenemases.
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combined three CDTs was observed when using cloxacillin
containing agar (sensitivity 100% and 84.6% for Mueller-
Hinton agar with and without cloxacillin, respectively; see
Table 6). Overall specificity was equal for both media types
(97.4%). Two of the 13 ESBL-positive isolates in AmpC pro-
ducers would have been missed by all CDTs using conven-
tional Mueller-Hinton agar, while CDTs on Mueller-Hinton
agar with cloxacillin detected all 13 ESBLs.
Two isolates were considered as ‘borderline results’ with
the CDT combination, because merely one CDT showed a
diameter difference of £7 mm. In these two isolates TEM-,
SHV- and CTX-M type ESBLs could not be detected by
molecular methods (Table 1).
In total, 23 K. oxytoca isolates were analysed: 17 were
putative ESBL producers, six served as a negative control
group (Table 1). Of the 17 isolates positive in the ESBL
screening, one isolate was correctly identified as SHV type
ESBL by the ceftazidime, cefotaxime and cefepime CDTs. A
second K. oxytoca isolate with a negative result in the ceftazi-
dime CDT and positive results in the cefotaxime and cefe-
pime CDTs was identified as CTX-M group 1 type ESBL by
PCR (false-negative ceftazidime CDT). In a third K. oxytoca
isolate with positive results in the cefotaxime and cefepime
CDTs but a negative result in the ceftazidime CDT the pres-
ence of an ESBL could not be confirmed by molecular meth-
ods (false-positive cefotaxime and cefepime CDTs). The
remaining 20 isolates showed congruent results between
phenotypic and genotypic tests. All 23 K. oxytoca isolates
would have been correctly assigned as ESBL positive (two
isolates) and ESBL negative (21 isolates) by the proposed
flow chart (see below).
Proposed flow chart for ESBL detection in
Enterobacteriaceae
Evaluating the results of the various screening and confirma-
tion assays we aimed to use this information to propose a
flow chart for reliable and standardized ESBL detection in
Enterobacteriaceae. The proposed procedure is based on: (i)
cefpodoxime and ceftriaxone diameters combined with the
clavulanic acid DDST as the primary screening markers; (ii)
CDTs using ceftazidime, cefotaxime and cefepime combined
as phenotypic confirmation tests; (iii) ceftazidime CDT for
K. oxytoca in combination with a CTX-M type PCR added in
case of a negative result; and (iv) molecular methods added
in the case of borderline results with CDTs. For ESBL detec-
tion the sensitivity and specificity of the phenotypic algorithm
alone would have been 100% and 97.5%, respectively, for the
isolates investigated in this study (Fig. 1 and Table 5). Adding
molecular methods (required for resolution of borderline
phenotypic confirmation tests) would increase specificity to
100%. Extrapolated to the 2518 study isolates (both initial
ESBL screening positives and negatives) the ESBL detection
algorithm would have displayed a sensitivity, specificity, PPV
and NPV each of 100% (see Table 4).
Discussion
Detection of ESBL is potentially critical to ensure adequate
therapy and to guide epidemiological and hospital hygiene
measures [13,20,21]. Laboratory methods for screening and
confirmation of ESBL should be accurate, simple and rapid.
During the past decades several phenotypic and molecular
tests have been evaluated for ESBL detection [13,14,22],
though a comprehensive algorithm is lacking. Molecular
methods have been suggested as screening methods for ESBL
[23–25]. However, in routine clinical diagnostic laboratories
implementation of molecular methods is often hampered by
the complexity of these assays, personnel needs and associ-
ated costs. Hence, an integrative approach combining pheno-
typic and molecular methods seems to be best suited for
optimal and cost-efficient ESBL detection. This study aimed
to develop an integrated phenotypic and molecular algorithm
for the detection of ESBL production in Enterobacteriaceae.
Automated phenotypic methods were not considered in our
study because these methods: (i) reportedly show weak-
nesses in sensitivity and specificity; and (ii) include E. coli and
Klebsiella spp. in their expert systems only [14,26–31].
Detection of ESBL is based on a combination of sensitive
screening and confirmation assays. First, we evaluated the
use of third-generation cephalosporin critical diameters and
DDSTs as primary ESBL screening tests. Ceftriaxone critical
diameters demonstrated highest sensitivity (98.4%) as a single
substance (Table 5). One ESBL isolate, however, was
detected exclusively by cefpodoxime. The combination of
ceftriaxone and cefpodoxime was the most sensitive screen-
ing parameter (99.2%). Addition of cefotaxime as a third sub-
stance did not improve sensitivity, but resulted in a decrease
of specificity (see Table 5). We do not consider ceftazidime
as a primary screening marker on its own because sensitivity
was low (72.6%) and no ESBL-producing isolate was exclu-
sively detected by ceftazidime. This finding is most probably
related to the higher hydrolytic activity of CTX-M type
enzymes on cefotaxime compared with ceftazidime [32]. Sen-
sitivity of ceftazidime in a population with an increased pro-
portion of SHV-type ESBLs may possibly be higher.
However, predominance of CTX-M type ESBLs in our study
population closely resembles the epidemiological situation in
Europe and North America [33–35]. Our results are in
agreement with other studies, which showed: (i) cefpodox-
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ime critical diameters to be highly sensitive for ESBL detec-
tion, but poorly specific; and (ii) combinations of third-gener-
ation cephalosporin critical diameters to result in a higher
specificity [31,36]. Critical diameters of third-generation
cephalosporins alone or in combination, however, were not
able to detect all ESBLs, but combining critical diameters of
cefpodoxime and ceftriaxone with DDST for cefpodoxime
resulted in a sensitivity of 100% for ESBL screening (Table 5).
Thus, a combination of three disks was required for initial
and sensitive screening: cefpodoxime, ceftriaxone and amoxi-
cillin-clavulanic acid. In particular, for AmpC b-lactamase-pro-
ducing species, such as E. cloacae, our results parallel the
data reported previously [14,22].
After determination of the most sensitive screening proce-
dure, we evaluated the CDT as an inexpensive and simple phe-
notypic confirmation method. The Etest ESBL (bioMe´rieux) is
widely used, but was not evaluated in this study for several
reasons. The test: (i) shows low specificity for ESBL produc-
tion in Enterobacteriaceae isolates other than E. coli; (ii) is signif-
icantly more expensive than the CDT; and (iii) was shown to
be unreliable if used with isolates producing AmpC b-lacta-
mases [14,37]. ESBLs may be missed by phenotypic confirma-
tion tests if an AmpC enzyme is present. For example, in this
study all false-negative results with the ceftazidime CDT
occurred in E. cloacae isolates overexpressing AmpC [25].
Thus, two modifications of the CLSI recommended CDT were
evaluated: (i) performing CDT for AmpC-producing isolates
on Mueller-Hinton agar containing cloxacillin that suppresses
AmpC activity; and (ii) addition of a cefepime CDT [38]. Our
results for the CDT comparing Mueller-Hinton agar with and
without cloxacillin show a significantly enhanced sensitivity for
the cloxacillin-containing plates (see Table 6). Cefepime is
poorly hydrolysed by AmpC enzymes. Addition of a cefepime
CDT can, thus, improve the performance of the CLSI recom-
mended cefotaxime and ceftazidime CDTs in the present epi-
demiological setting with ESBLs frequently present in species
producing AmpC b-lactamases. None of the three CDTs
applied alone resulted in a sensitivity of 100% (Table 5). In
contrast, combining three CDT substances including cefepime
proved to be highly sensitive and specific (sensitivity and speci-
ficity of 100% and 97.5%, respectively). If performance param-
eters were calculated for AmpC-producing isolates alone the
cefepime CDT displayed sensitivity and specificity both of
100% using Mueller-Hinton agar with cloxacillin (Table 6). All
false-negative results in AmpC-producing species listed in
Table 6 were seen in E. cloacae isolates overexpressing AmpC
using Mueller-Hinton agar without cloxacillin. Our results for
the three CDTs are in agreement with data from other studies
[14,39]. The ceftazidime CDT did not exclusively detect any
ESBL-positive isolate. Omitting ceftazidime CDT as a confir-
mation test, however, cannot be recommended because ceft-
azidime is recommended for ESBL confirmation in K. oxytoca
by EUCAST to avoid false-positive results with cefotaxime
[40]. According to EUCAST rules, one ceftazidime CDT nega-
tive, cefotaxime and cefepime CDT positive K. oxytoca isolate
overexpressing K1-b-lactamase was correctly identified as
ESBL negative in our study. For K. oxytoca the ceftazidime
CDT alone should, therefore, be considered as a phenotypic
confirmation test to avoid false-positive results. If the ceftazi-
dime CDT gives a negative result a CTX-M type PCR should
be carried out for isolates screening positive for ESBL because
a ceftazidime CDT negative isolate may have a CTX-M type
ESBL (one isolate in this study, Table 1).
Combining three CDTs facilitated correct assignment of
borderline CDT results to the ESBL positive or negative cat-
egory. We considered results borderline or inconclusive if
merely one of the three CDTs was marginally positive
(Fig. 1) Usually, such isolates would be classified as ESBL
positive because one positive CDT alone is considered indic-
ative of ESBL [10]. The two isolates considered ‘borderline’
were subjected to molecular confirmation methods and were
shown to be ESBL negative. To define and resolve ‘border-
line’ criteria further studies with higher numbers of border-
line CDT results are needed.
One possible concern is that the increasing prevalence of
carbapenemases will interfere with this diagnostic algorithm.
In the case of metallo-carbapenemase producers like NDM-1,
CDTs with clavulanic acid would most likely give negative or
inconclusive test results because those enzymes are charac-
teristically not inhibited by clavulanic acid [41]. Carbapene-
mases of Ambler class A (e.g. Klebsiella pneumoniae
carbapenemase, KPC) that are inhibited by clavulanic acid
could produce false-positive CDTs. Isolates harbouring car-
bapenemases are, however, readily detected by the use of
carbapenems as screening markers [42]. All 2518 isolates
included in this study were categorized as susceptible to im-
ipenem, meropenem and ertapenem according to CLSI 2009
guidelines [10]. All ESBL suspicious, but ESBL confirmation
test negative, isolates in this study have been additionally
checked for the presence of KPC by PCR and were found
to be KPC negative (data not shown).
In summary, the proposed diagnostic flow chart (Fig. 1)
would have resulted in a sensitivity and specificity of 100%
for ESBL detection in the isolates tested. This algorithm is
accurate, simple, easy to use, inexpensive and, therefore,
applicable in the standard routine clinical microbiology labo-
ratory. In the case of inconclusive results, which will rarely
(<1%) occur, molecular methods are recommended. Such a
diagnostic flow chart may be automatized in an open expert
system as described by Winstanley et al. [43].
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